Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks
The rise in liver disease incidence and prevalence has led to increasing morbidity and mortality worldwide. Persistent hepatic inflammation drives disease progression by increasing fibrosis, advancing to cirrhosis, and potentially developing into hepatocellular carcinoma (HCC). Addressing these comp...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/14/12/1701 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850049926876102656 |
|---|---|
| author | Amani Elshaer Blanca C. Lizaola-Mayo |
| author_facet | Amani Elshaer Blanca C. Lizaola-Mayo |
| author_sort | Amani Elshaer |
| collection | DOAJ |
| description | The rise in liver disease incidence and prevalence has led to increasing morbidity and mortality worldwide. Persistent hepatic inflammation drives disease progression by increasing fibrosis, advancing to cirrhosis, and potentially developing into hepatocellular carcinoma (HCC). Addressing these complications is essential to reduce liver-related mortality. Recent studies suggest that non-steroidal anti-inflammatory drugs, particularly aspirin, may play a beneficial role in managing liver disease. Aspirin’s anti-inflammatory and chemoprotective effects contribute to slowing disease progression and reducing the risks associated with chronic liver disease (CLD). This review highlights the current literature on the effects of aspirin in CLD, with a focus on patients with metabolic-associated steatotic liver disease (MASLD) and hepatitis B and C. We will examine aspirin’s potential ability to mitigate fibrosis, reduce the incidence of HCC, and lower liver-related mortality. Additionally, we will discuss its potential side effects and safety considerations, particularly in the context of liver disease, where there is an increased risk of bleeding. |
| format | Article |
| id | doaj-art-a4b0b704b3b549a0b7bfb58610858d80 |
| institution | DOAJ |
| issn | 2075-1729 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj-art-a4b0b704b3b549a0b7bfb58610858d802025-08-20T02:53:37ZengMDPI AGLife2075-17292024-12-011412170110.3390/life14121701Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and RisksAmani Elshaer0Blanca C. Lizaola-Mayo1Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USADivision of Gastroenterology, Hepatology and Transplant Hepatology, Mayo Clinic, Phoenix, AZ 85054, USAThe rise in liver disease incidence and prevalence has led to increasing morbidity and mortality worldwide. Persistent hepatic inflammation drives disease progression by increasing fibrosis, advancing to cirrhosis, and potentially developing into hepatocellular carcinoma (HCC). Addressing these complications is essential to reduce liver-related mortality. Recent studies suggest that non-steroidal anti-inflammatory drugs, particularly aspirin, may play a beneficial role in managing liver disease. Aspirin’s anti-inflammatory and chemoprotective effects contribute to slowing disease progression and reducing the risks associated with chronic liver disease (CLD). This review highlights the current literature on the effects of aspirin in CLD, with a focus on patients with metabolic-associated steatotic liver disease (MASLD) and hepatitis B and C. We will examine aspirin’s potential ability to mitigate fibrosis, reduce the incidence of HCC, and lower liver-related mortality. Additionally, we will discuss its potential side effects and safety considerations, particularly in the context of liver disease, where there is an increased risk of bleeding.https://www.mdpi.com/2075-1729/14/12/1701aspirinchronic liver diseasehepatocellular carcinomametabolic-associated steatotic liver disease |
| spellingShingle | Amani Elshaer Blanca C. Lizaola-Mayo Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks Life aspirin chronic liver disease hepatocellular carcinoma metabolic-associated steatotic liver disease |
| title | Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks |
| title_full | Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks |
| title_fullStr | Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks |
| title_full_unstemmed | Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks |
| title_short | Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks |
| title_sort | evaluating the role of aspirin in liver disease efficacy safety potential benefits and risks |
| topic | aspirin chronic liver disease hepatocellular carcinoma metabolic-associated steatotic liver disease |
| url | https://www.mdpi.com/2075-1729/14/12/1701 |
| work_keys_str_mv | AT amanielshaer evaluatingtheroleofaspirininliverdiseaseefficacysafetypotentialbenefitsandrisks AT blancaclizaolamayo evaluatingtheroleofaspirininliverdiseaseefficacysafetypotentialbenefitsandrisks |